122 related articles for article (PubMed ID: 8229769)
1. ATP-sensitive potassium channels and skeletal muscle function in vitro.
Weselcouch EO; Sargent C; Wilde MW; Smith MA
J Pharmacol Exp Ther; 1993 Oct; 267(1):410-6. PubMed ID: 8229769
[TBL] [Abstract][Full Text] [Related]
2. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
3. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
Grover GJ
J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
[TBL] [Abstract][Full Text] [Related]
4. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
[TBL] [Abstract][Full Text] [Related]
5. Potassium channel modulation: a new drug principle for regulation of smooth muscle contractility. Studies on isolated airways and arteries.
Nielsen-Kudsk JE
Dan Med Bull; 1996 Dec; 43(5):429-47. PubMed ID: 8960816
[TBL] [Abstract][Full Text] [Related]
6. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
[TBL] [Abstract][Full Text] [Related]
7. Epithelium-dependent inhibition of cholinergic transmission in rat isolated trachea by potassium channel openers.
Fabiani ME; Vlahos R; Story DF
Pharmacol Res; 1996; 33(4-5):261-72. PubMed ID: 8938019
[TBL] [Abstract][Full Text] [Related]
8. Effect of KATP channel openers on myogenic and neurogenic responses in goat urinary bladder.
Vijayakumar C; Kathirvel K; Sardar KK; Parija SC
Indian J Exp Biol; 2007 Feb; 45(2):185-93. PubMed ID: 17375559
[TBL] [Abstract][Full Text] [Related]
9. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
[TBL] [Abstract][Full Text] [Related]
10. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of the potassium channel openers cromakalim and pinacidil and the cromakalim analog U-89232 on isolated vascular and cardiac tissue.
Norman NR; Toombs CF; Khan SA; Buchanan LV; Cimini MG; Gibson JK; Meisheri KD; Shebuski RJ
Pharmacology; 1994 Aug; 49(2):86-95. PubMed ID: 7972325
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
[TBL] [Abstract][Full Text] [Related]
13. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts?
Tosaki A; Szerdahelyi P; Engelman RM; Das DK
J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of ATP-sensitive K+ channels in mammalian skeletal muscle cells.
Allard B; Lazdunski M
Eur J Pharmacol; 1993 Jun; 236(3):419-26. PubMed ID: 8359200
[TBL] [Abstract][Full Text] [Related]
15. Vascular pharmacology of ATP-sensitive K+ channels: interactions between glyburide and K+ channel openers.
Meisheri KD; Khan SA; Martin JL
J Vasc Res; 1993; 30(1):2-12. PubMed ID: 8435468
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
Tosaki A; Engelman DT; Engelman RM; Das DK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of pinacidil, cromakalim, and NS 1619 on electrically evoked contractions in rat vas deferens.
Huang Y; Lau CW
Zhongguo Yao Li Xue Bao; 1997 Jul; 18(4):293-8. PubMed ID: 10072907
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
[TBL] [Abstract][Full Text] [Related]
19. Mechanical and energetic effects of cromakalim on guinea pig left ventricular papillary muscle.
Joseph T; Coirault C; Ducros L; Lecarpentier Y
J Pharmacol Exp Ther; 1996 Nov; 279(2):464-71. PubMed ID: 8930147
[TBL] [Abstract][Full Text] [Related]
20. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
